Liberum Capital Ltd Reaffirms Neutral Rating on AstraZeneca (AZN)
AstraZeneca (LON: AZN)‘s stock had its “neutral” rating reaffirmed by research analysts at Liberum Capital Ltd in a report released on Friday. They currently have a $48.57 (3000 GBX) target price on the stock.
AstraZeneca opened at 2906.50 on Friday. AstraZeneca has a 52-week low of GBX 2578.50 and a 52-week high of GBX 3116.50. The company’s market cap is £36.593 billion.
AZN has been the subject of a number of other recent research reports. Analysts at Nomura reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a $38.57 price target on the stock. Separately, analysts at Panmure Gordon & Co Limited reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Wednesday. They now have a $48.42 price target on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a $41.94 price target on the stock.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.